This is what happens, for example, by using a combined treatment based on mammalian target of rapamycin (mTOR) inhibitor and TMZ in GBM: this treatment sustains the induction of the autophagic onset, favoring cell death. The gene discussed is MTOR; the disease is glioblastoma.